Larysa Sanchez

1.2k total citations
65 papers, 606 citations indexed

About

Larysa Sanchez is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Larysa Sanchez has authored 65 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Hematology, 33 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in Larysa Sanchez's work include Multiple Myeloma Research and Treatments (47 papers), CAR-T cell therapy research (18 papers) and Protein Degradation and Inhibitors (15 papers). Larysa Sanchez is often cited by papers focused on Multiple Myeloma Research and Treatments (47 papers), CAR-T cell therapy research (18 papers) and Protein Degradation and Inhibitors (15 papers). Larysa Sanchez collaborates with scholars based in United States, United Kingdom and Canada. Larysa Sanchez's co-authors include David S. Siegel, Yucai Wang, Michael Wang, Joshua Richter, Shambavi Richard, Samir Parekh, Hearn Jay Cho, Sundar Jagannath, Ajai Chari and Deepu Madduri and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Larysa Sanchez

58 papers receiving 597 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Larysa Sanchez United States 12 376 335 253 122 118 65 606
Khalid Mezzi United States 12 499 1.3× 426 1.3× 411 1.6× 142 1.2× 100 0.8× 26 788
Shebli Atrash United States 13 521 1.4× 454 1.4× 403 1.6× 112 0.9× 73 0.6× 119 752
Susan Bal United States 13 503 1.3× 402 1.2× 410 1.6× 68 0.6× 68 0.6× 80 691
Jenna D. Goldberg United States 4 276 0.7× 275 0.8× 170 0.7× 106 0.9× 134 1.1× 12 467
Al‐Ola Abdallah United States 14 534 1.4× 550 1.6× 414 1.6× 85 0.7× 99 0.8× 134 871
Caitlin Costello United States 17 455 1.2× 519 1.5× 463 1.8× 157 1.3× 140 1.2× 64 910
Raya Mawad United States 13 264 0.7× 214 0.6× 127 0.5× 98 0.8× 88 0.7× 38 459
Nisha S. Joseph United States 13 645 1.7× 389 1.2× 498 2.0× 68 0.6× 63 0.5× 69 783
Antonio Capaldi Italy 12 332 0.9× 397 1.2× 261 1.0× 121 1.0× 43 0.4× 20 663
Lori A. Ehrlich United States 9 409 1.1× 465 1.4× 302 1.2× 84 0.7× 24 0.2× 20 707

Countries citing papers authored by Larysa Sanchez

Since Specialization
Citations

This map shows the geographic impact of Larysa Sanchez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larysa Sanchez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larysa Sanchez more than expected).

Fields of papers citing papers by Larysa Sanchez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larysa Sanchez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larysa Sanchez. The network helps show where Larysa Sanchez may publish in the future.

Co-authorship network of co-authors of Larysa Sanchez

This figure shows the co-authorship network connecting the top 25 collaborators of Larysa Sanchez. A scholar is included among the top collaborators of Larysa Sanchez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larysa Sanchez. Larysa Sanchez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aleman, Adolfo, Erin Moshier, Adriana Rossi, et al.. (2025). Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy. Clinical Cancer Research. 31(20). 4333–4344. 1 indexed citations
2.
3.
Mouhieddine, Tarek H., Tianxiang Sheng, Weijia Fu, et al.. (2025). Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma. Bone Marrow Transplantation. 60(8). 1114–1119.
4.
Sanchez, Larysa & Shambavi Richard. (2025). Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies. Seminars in Hematology. 62(1). 31–37. 1 indexed citations
5.
Chen, Lucia, Santiago Thibaud, Ajai Chari, et al.. (2024). MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma. Blood Advances. 9(1). 176–179.
6.
Morillo, Daniel, Carmen Martínez Chamorro, Luciano J. Costa, et al.. (2024). P-058 Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S74–S75. 1 indexed citations
7.
Schinke, Carolina, Ravi Vij, Sundar Jagannath, et al.. (2024). P-077 Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S86–S86. 2 indexed citations
8.
Popat, Rakesh, Alexa M. G. A. Laheij, Niels W.C.J. van de Donk, et al.. (2024). P-066 Prophylactic Interventions for Oral Toxicities With the GPRC5D×CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase 2, Randomized Study (TALISMAN). Clinical Lymphoma Myeloma & Leukemia. 24. S79–S80. 1 indexed citations
9.
10.
11.
Lancman, Guido, Lisa Avery, Hearn Jay Cho, et al.. (2023). IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discovery. 4(6). 440–451. 56 indexed citations
12.
Sanchez, Larysa, et al.. (2022). No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma. Blood Reviews. 57. 100993–100993. 1 indexed citations
13.
Sindhu, Kunal K., Erin Moshier, Joshua Richter, et al.. (2021). The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 22(3). 192–197. 6 indexed citations
14.
Sanchez, Larysa. (2021). Strategies to Overcome High-Risk Multiple Myeloma. The Cancer Journal. 27(3). 201–204.
15.
Mian, Hira, Mark A. Fiala, Larysa Sanchez, Ravi Vij, & Tanya M. Wildes. (2021). Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”. Annals of Hematology. 100(5). 1261–1266. 7 indexed citations
16.
Richter, Joshua, Larysa Sanchez, Noa Biran, et al.. (2020). Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(3). e284–e289. 15 indexed citations
17.
Richter, Joshua, Larysa Sanchez, & Santiago Thibaud. (2020). Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date. Seminars in Oncology. 47(2-3). 155–164. 10 indexed citations
18.
Wang, Yucai, Larysa Sanchez, David S. Siegel, & Michael Wang. (2016). Elotuzumab for the treatment of multiple myeloma. Journal of Hematology & Oncology. 9(1). 55–55. 43 indexed citations
19.
Sanchez, Larysa, Yucai Wang, David S. Siegel, & Michael Wang. (2016). Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. Journal of Hematology & Oncology. 9(1). 51–51. 123 indexed citations
20.
Sanchez, Larysa, et al.. (2015). Perceived competency and knowledge in palliative and end-of-life care among physicians at an academic institution.. Journal of Clinical Oncology. 33(29_suppl). 59–59. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Khalid Mezzi Breakdown of academic impact, for papers by Shebli Atrash Breakdown of academic impact, for papers by Susan Bal Breakdown of academic impact, for papers by Jenna D. Goldberg Breakdown of academic impact, for papers by Al‐Ola Abdallah Breakdown of academic impact, for papers by Caitlin Costello Breakdown of academic impact, for papers by Raya Mawad Breakdown of academic impact, for papers by Nisha S. Joseph Breakdown of academic impact, for papers by Antonio Capaldi Breakdown of academic impact, for papers by Lori A. Ehrlich
Rankless by CCL
2026